Inmune Stock News

Management to host conference call and webcast at 4:30 pm ET on that day Management to host conference call and webcast at 4:30 pm ET on that day

INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.

Data from animal models of trastuzumab-resistant MUC4 HER2+ breast cancer show that treatment with INB03 decreases MUC4 expression, reverses resistance to trastuzumab and tyrosine kinase inhibitors, a

INKmune therapy, NK cell therapy, was shown to activate NK cells that killed off >70% of NK resistant tumor cells in an in vitro assay in an MDS patient.

INmune Bio, Inc. (INMB) CEO Raymond J. Tesi on Q4 2021 Results - Earnings Call Transcript

INmune Bio press release (INMB): Q4 GAAP EPS of -$1.88 misses by $1.30.Revenue of $0.18M (+63.6% Y/Y).

Management to host conference call and webcast at 4:30 pm ET on that day

BOCA RATON, Florida., Feb. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the pa

Both Cassava Sciences and INmune Bio have brought impressive results on neuroinflammation and neurodegeneration. I expect INmune Bio's XPro to yield impressive results in its phase 2 trials like Cassa

Boca Raton, Florida, Jan. 04, 2022 (GLOBE NEWSWIRE) -- INmune  Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the p

Analysts forecast that INmune Bio, Inc. (NASDAQ:INMB) will post earnings per share of ($0.56) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for INmune Bios earnings. INmune Bio reported earnings of ($0.24) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of []

Zacks Investment Research cut shares of INmune Bio (NASDAQ:INMB) from a hold rating to a sell rating in a report issued on Thursday morning, Zacks.com reports. According to Zacks, INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The companys product platform consists of []

INmune Bio, Inc. (INMB) CEO R. J. Tesi on Q3 2021 Results - Earnings Call Transcript

Management to host conference call and webcast at 4:30 pm ET on that day Management to host conference call and webcast at 4:30 pm ET on that day